Gut mucosa-associated microbiota signatures in healthy individuals and patients at different stages of liver disease: a pilot study
Rattachement africain : it, es, in. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The gut microbiota plays a key role in the progression of chronic liver disease and the development of hepatocellular carcinoma (HCC). However, findings on microbiota composition in such patients remain inconsistent, likely due to differences in disease aetiology and sample type. The mucosa-associated microbiota (MAM), residing in the intestinal mucin layer, more accurately reflects mucosal health than faecal microbiota, being more stable and less influenced by diet. This study aimed to characterise the ileal and sigmoid MAM in patients with chronic hepatitis C (CHC), liver cirrhosis (LC), and HCC. METHODS: We performed DNA metabarcoding sequencing of mucosa samples collected from the ileum and sigmoid colon of patients at different stages of liver disease and healthy controls (HC). The predicted functions were analysed via phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt2) to infer metabolic pathways that can be expressed in the microbiome. RESULTS: Among 33 participants (20 HCV-related liver disease and 13 healthy controls), MAM α-diversity decreased significantly in advanced disease stages, particularly in LC and HCC, regardless of the metric applied (p ≤ 0.05). β-diversity analyses showed distinct microbial community structures across groups. Both ileal and sigmoid MAM were dominated by Bacteroidetes, Firmicutes, and Proteobacteria, with enrichment of Firmicutes_D, Proteobacteria, and Fusobacteria in LC and HCC. Several genera, including Bulleidia, Pantoea, Clostridium_Q, Rothia, and Streptococcus, were significantly increased in HCC, whereas beneficial taxa such as Akkermansia and Butyricimonas were depleted. Functional predictions indicated enrichment of degradative pathways (e.g., taurine, chitin derivatives, and carbohydrate metabolism) in LC and HCC. CONCLUSION: Our pilot study suggests that MAM alterations do not directly mirror liver disease progression but show distinct patterns associated with different stages. These associations, more evident in advanced disease, involve bacterial taxa linked to gut integrity, inflammation, and carcinogenesis. This exploratory work lays the groundwork for future studies to validate these findings and investigate their relevance to microbiome-based diagnostics and therapies in HCC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Gut mucosa-associated microbiota signatures in healthy individuals and patients at different stages of liver disease: a pilot study
- Date Crossref
- 08/12/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Federico II University Hospital Department of Clinical Medicine and Surgery pays non établi dans la noticeÉtablissement de santé
-
University of Bari Aldo Moro Department of Biosciences pays non établi dans la noticeUniversité ou école supérieure
-
CEINGE Biotecnologie Avanzate Franco Salvatore (Italy) pays non établi dans la noticeEntreprise
-
University of Naples Federico II Department of Molecular Medicine and Medical Biotechnologies pays non établi dans la noticeUniversité ou école supérieure
-
San Raffaele University of Rome pays non établi dans la noticeUniversité ou école supérieure
-
Institute for High Performance Computing and Networking pays non établi dans la noticeStructure de recherche
-
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer pays non établi dans la noticeStructure de recherche
-
Institute of Bioinformatics pays non établi dans la noticeOrganisation à but non lucratif
-
San Raffaele Open University Department of Human Sciences and Quality of Life Promotion pays non établi dans la noticeUniversité ou école supérieure
-
Computational and Data Science Laboratory pays non établi dans la noticeStructure de recherche
-
University of Barcelona Institute Investigations pays non établi dans la noticeUniversité ou école supérieure
-
Department of Bioinformatics pays non établi dans la noticeInstitution
Department of Clinical Medicine and Surgery — Federico II University Hospital, Department of Biosciences — University of Bari Aldo Moro et CEINGE Biotecnologie Avanzate Franco Salvatore (Italy), avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.